Alliance Pharma and Drug Development Solutions Are Now Resolian

News - Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.

17 May 2023
Development and validation of an immunogenicity assay for detection of anti-AAV antibodies

Blog - Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. The AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy.

13 March 2023
The Australia Advantage – Why You Should Consider Conducting Clinical Trials in Australia

Blog - Accelerate timelines, lower costs, and ensure quality for your clinical research in Australia. Our advanced scientific infrastructure and world-class experts attract trials from across the globe and meet their needs with the highest standards and efficient regulatory requirements. Explore the extensive benefits of Australia’s clinical research ecosystem >

08 March 2023
Making the conscious shift to adopting risk-based Computerised Systems Validation

Blog - In the 2023 Quarter 1 issue of RQA (Research Quality Association) 2023 Q1 Quasar magazine, John Cheshire, our Senior QA Validation Officer discusses why the industry should be adopting risk-based CSV.

23 February 2023
Drug Development Solutions Announces Significant Expansion of Analytical Laboratory Operations in Cambridge (Fordham), UK

News - The Analytical and Materials Science (AMS) team has experienced significant growth since its inception 11 years ago and have outgrown their current lab space.  To meet this rising demand, we have started work on reimagining an empty area of our site into a new state-of-the-art AMS laboratory. This lab will be over 30% larger, providing over 440 square metres of dedicated space for analytical and materials science work. 

20 February 2023
Webinar | Challenges of developing ADA and concentration (PK or PD) assays for lysosomal transgene enzymes

Blog - One of the biggest challenges faced by the bioanalytical sector is the lack of a true reference material. As a result, in most assays, an alternative commercially available therapeutic (for example, an enzyme replacement therapy (ERT) product) can be used as a surrogate for the transgene enzyme. This webinar discusses approaches taken in order to monitor the concentration of the expressed transgene product and any associated immunogenicity.

10 February 2023
How To Build a Comprehensive Response to Client Needs as a CRO

Blog - As a CRO, meeting client expectations can be an ongoing challenge. What can organisations do to make sure their research is as effective and efficient as possible? In the Autumn 2022 issue of European Pharmaceutical Contractor magazine, the leadership team from Alliance Pharma reviews what CRO organisations can do to make sure their research is as effective and efficient as possible while meeting the ongoing challenge of their customer's expectations.

27 January 2023
AMS Sandwich Celebrates 10th Anniversary

Blog - Analytical and Materials Science (AMS) Sandwich Team recently celebrated their 10th Anniversary in an event marking Discovery Park’s 10th Anniversary. AMS Sandwich was founded in 2012 at Discovery Park – Kent’s largest science and innovation park situated just outside of the historic town of Sandwich. The team, initially comprising a few members, was formed with the aim of plugging a gap identified in the ‘Materials Science’ area of pharmaceutical development.

05 December 2022
The next chapter in Nitrosamine Testing

Blog - Based on industry feedback following the recent requirements regarding risk assessments of marketed products, a significant amount of small molecule related APIs, possibly 30%+, have been shown to have the potential to form active related nitrosamines

01 December 2022
Presentation Slides - The Importance of Good Experimental Design for Extractable and Leachable Studies

Blog - AMS Science Lead Mike Ludlow explains the importance of good experimental design for extractable and leachable studies.

10 November 2022